| Name | Title | Contact Details |
|---|---|---|
Bryan Healy |
Vice President & General Counsel | Profile |
The Denver Public Library (DPL) is a public library system serving the city of Denver, Colorado. Established in 1889, it has grown into a vital community resource with 27 locations throughout the city. The library offers a wide range of services, including early literacy programs for children, digital access with computer training, and various community programs such as workshops and cultural events. DPL provides access to a vast collection of materials, including books, audiobooks, e-books, and DVDs. It also offers digital resources like databases and online courses. The library features special collections, including the Western History and Genealogy Department and the Blair-Caldwell African American Research Library. Its mission is to create welcoming spaces for exploration and connection, emphasizing values such as curiosity, equity, and community engagement.
AI REV is a boutique AI consulting company with partners having extensive practical AI experience and strong track records. We provide state-of-the-art consulting & AI project delivery for enterprise clients. AI REVs goal is to reduce the average human workweek from 40 hours to 20. We are working towards achieving this by augmenting companies with AI-powered efficiency improvements. Our solutions have saved our customers up to 25% on related departamental costs, substantially decreased their operational risk, and enabled the reallocation of manpower to more pressing issues. We offer end-to-end Machine Learning, Data Science, AI & software development, Strategic Consulting, and Engineering Workshops.
Mazars is an internationally integrated partnership, specialising in audit, accountancy, advisory, tax and legal services*. Operating in over 100 countries and territories around the world, we draw on the expertise of more than 50,000 professionals – 33,000+ in Mazars integrated partnership and 17,000+ via the Mazars North America Alliance – to assist clients of all sizes at every stage in their development. *Where permitted under applicable country laws
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.